Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy

Human Gene Therapy Methods

Volumn 24, Issue 2, 2013, Pages 59-67

  Louis Jeune, Vedell ^a   Joergensen, Jakob A ^a   Hajjar, Roger J ^a   Weber, Thomas ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; CYCLOSPORIN A; EPITOPE; IMMUNOGLOBULIN; NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR; RECOMBINANT BLOOD CLOTTING FACTOR 9; RITUXIMAB; VIRUS ANTIBODY;

ADENO ASSOCIATED VIRUS; ALPHA 1 ANTITRYPSIN DEFICIENCY; ANTIBODY TITER; CELLULAR IMMUNITY; CHEMICAL MODIFICATION; DNA SHUFFLING; DNA VECTOR; GENE MUTATION; GENE TRANSFER; GENETIC TRANSDUCTION; GROUPS BY AGE; HUMAN; HUMORAL IMMUNITY; MOLECULAR EVOLUTION; MUTAGENESIS; NONHUMAN; PLASMAPHERESIS; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SEROTYPE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CAPSID; VIRUS RECOMBINANT;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAPSID PROTEINS; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MUTATION; PLASMAPHERESIS; SEROEPIDEMIOLOGIC STUDIES; TRANSDUCTION, GENETIC;

ADENO-ASSOCIATED VIRUS;

EID: 84878746264     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2012.243     Document Type: Review

References (67)

1. Asokan, A., Schaffer, D.V., and Samulski, R.J. (2012). The AAV vector toolkit: poised at the clinical crossroads. Mol. Ther. 20, 699-708.
2. Atchison, R.W. (1970). The role of herpesviruses in adenovirusassociated virus replication in vitro. Virology 42, 155-62.
3. Atchison, R.W., Casto, B.C., and Hammon W.M. (1965). Adenovirus associated defective virus particles. Science 149, 754-6.
4. Bartel, M., Schaffer, D., and Buning H. (2011). Enhancing the clinical potential of AAV vectors by capsid engineering to evade pre-existing immunity. Front Microbiol. 2, 204.
5. Beckman, R.A., Mildvan, A.S., and Loeb, L.A. (1985). On the fidelity of DNA replication: manganese mutagenesis in vitro. Biochemistry 24, 5810-7.
6. Blacklow, N.R., Hoggan, M.D., Kapikian, A.Z., et al. (1968). Epidemiology of adenovirus-associated virus infection in a nursery population. Am. J. Epidemiol. 88, 368-78.
7. Boutin, S., Monteilhet, V., Veron, P., et al. (2010). Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther. 21, 704-12.
8. Calcedo, R., Vandenberghe, L.H., Gao, G., et al. (2009). Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J. Infect. Dis. 199, 381-90.
9. Calcedo, R.,Morizono, H.,Wang, L., et al. (2011). Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin. Vaccine Immunol. 18, 1586-8.
10. Carlisle, R.C., Benjamin, R., Briggs, S.S., et al. (2008). Coating of adeno-associated virus with reactive polymers can ablate virus tropism, enable retargeting and provide resistance to neutralising antisera. J. Gene Med. 10, 400-11.
11. Cassinotti, P., Weitz, M., and Tratschin, J.D. (1988). Organization of the adeno-associated virus (AAV) capsid gene: mapping of a minor spliced mRNA coding for virus capsid protein 1. Virology 167, 176-84.
12. Chaput, J.C., Woodbury, N.W., Stearns, L.A., and Williams, B.A. (2008). Creating protein biocatalysts as tools for future industrial applications. Expert Opin. Biol. Ther. 8, 1087-98.
13. Chirmule, N., Propert, K., Magosin, S., et al. (1999). Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 6, 1574-83.
14. Clark, K.R., Sferra, T.J., and Johnson, P.R. (1997). Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle. Hum. Gene Ther. 8, 659-69.
15. Cline, J., Braman, J.C., and Hogrefe, H.H. (1996). PCR fidelity of pfu DNA polymerase and other thermostable DNA polymerases. Nucleic Acids Res. 24, 3546-51.
16. Croyle, M.A., Chirmule, N., Zhang, Y., and Wilson, J.M. (2001). "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J. Virol. 75, 4792-801.
17. Croyle, M.A., Chirmule, N., Zhang, Y., and Wilson, J.M. (2002). PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum. Gene Ther. 13, 1887-900.
18. Davidoff, A.M., Gray, J.T., Ng, C.Y., et al. (2005). Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol. Ther. 11, 875-88.
19. Dube, D.K., and Loeb, L.A. (1975). Manganese as a mutagenic agent during in vitro DNA synthesis. Biochem. Biophys. Res. Commun. 67, 1041-6.
20. Eckert, K.A., and Kunkel, T.A. (1991). DNA polymerase fidelity and the polymerase chain reaction. PCR Methods Appl. 1, 17-24.
21. Erles, K., Sebökovà, P., and Schlehofer, J.R. (1999). Update on the prevalence of serum antibodies (IgG and IgM) to adenoassociated virus (AAV). J. Med. Virol. 59, 406-11.
22. Flotte, T.R., Trapnell, B.C., Humphries, M., et al. (2011). Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha1-antitrypsin: interim results. Hum. Gene Ther. 22, 1239-47.
23. Gao, G., Vandenberghe, L.H., Alvira, M.R., et al. (2004). Clades of Adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78, 6381-8.
24. Gao, G.P., Alvira, M.R., Wang, L., et al. (2002). Novel adenoassociated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U S A 99, 11854-9.
25. Gruber, K. (2012). Europe gives gene therapy the green light. Lancet 380, e10.
26. Gurda, B.L., Raupp, C., Popa-Wagner, R., et al. (2012). Mapping a neutralizing epitope onto the capsid of adeno-associated virus serotype 8. J. Virol. 86, 7739-51.
27. Halbert, C.L., Rutledge, E.A., Allen, J.M., et al. (2000). Repeat transduction in the mouse lung by Using adeno-associated virus vectors with different serotypes. J. Virol. 74, 1524-32.
28. Harris, J.M., and Chess, R.B. (2003). Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2, 214-21.
29. Hermonat, P.L., and Muzyczka, N. (1984). Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc. Natl. Acad. Sci. USA 81, 6466-70.
30. Hurlbut, G.D., Ziegler, R.J., Nietupski, J.B., et al. (2010). Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy. Mol. Ther. 18, 1983-94.
31. Kerr, J.R. (2006). Parvoviruses. Hodder Arnold; distributed in the United States by Oxford University Press, London/New York.
32. Kotin, R.M., Linden, R.M., and Berns, K.I. (1992). Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J. 11, 5071-8.
33. Kotin, R.M., Siniscalco, M., Samulski, R.J., et al. (1990). Sitespecific integration by adeno-associated virus. Proc. Natl. Acad. Sci. U.S.A. 87, 2211-5.
34. Labrou, N.E. (2010). Random mutagenesis methods for in vitro directed enzyme evolution. Curr. Protein Pept. Sci. 11, 91-100.
35. Le, H.T., Yu, Q.C., Wilson, J.M., and Croyle, M.A. (2005). Utility of PEGylated recombinant adeno-associated viruses for gene transfer. J. Control Release 108, 161-77.
36. Lee, G.K., Maheshri, N., Kaspar, B., and Schaffer, D.V. (2005). PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization. Biotechnol. Bioeng. 92, 24-34.
37. Linden, R.M., Ward, P., Giraud, C., et al. (1996). Site-specific integration by adeno-associated virus. Proc. Natl. Acad. Sci. U.S.A. 93, 11288-94.
38. Lochrie, M.A., Tatsuno, G.P., Christie, B., et al. (2006). Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization. J. Virol. 80, 821-34.
39. Lusby, E., Fife, K.H., and Berns K.I. (1980). Nucleotide sequence of the inverted terminal repetition in adeno-associated virus DNA. J. Virol. 34, 402-9.
40. Lusby, E., Bohenzky, R., and Berns, K.I. (1981). Inverted terminal repetition in adeno-associated virus DNA: independence of the orientation at either end of the genome. J. Virol. 37, 1083-6.
41. Maersch, S., Huber, A., Büning, H., et al. (2010). Optimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes. Virology 397, 167-75.
42. Maheshri, N., Koerber, J.T., Kaspar, B.K., and Schaffer, D.V. (2006). Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol. 24, 198-204.
43. Mendelson, E., Trempe, J.P., and Carter, B.J. (1986). Identification of the trans-acting Rep proteins of adeno-associated virus by antibodies to a synthetic oligopeptide. J. Virol. 60, 823-32.
44. Mingozzi, F., Hasbrouck, N.C., Basner-Tschakarjan, E., et al. (2007). Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood 110, 2334-41.
45. Mingozzi, F., Meulenberg, J.J., Hui, D.J., et al. (2009). AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood 114, 2077-86.
46. Mingozzi, F., Chen, Y., Edmonson, S.C., et al. (2012a). Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue. Gene Ther. [Epub ahead of print]; DOI: 10.1038/gt.2012.55
47. Mingozzi, F., Chen, Y., Murphy, S.L., et al. (2012b). Pharmacological Modulation of Humoral Immunity in a Nonhuman Primate Model of AAV Gene Transfer for Hemophilia B. Mol. Ther. 20, 1410-6.
48. Monteilhet, V., Saheb, S., Boutin, S., et al. (2011). A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol Ther. 19, 2084-91.
49. Moskalenko, M., Chen, L., Van Roey, M., et al. (2000). Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J. Virol. 74, 1761-6.
50. Murphy, S.L., Li, H., Mingozzi, F., et al. (2009). Diverse IgG subclass responses to adeno-associated virus infection and vector administration. J. Med. Virol. 81, 65-74.
51. Nathwani, A.C., Tuddenham, E.G., Rangarajan, S., et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365, 2357-65.
52. Nonnenmacher, M., and Weber, T. (2012). Intracellular transport of recombinant adeno-associated virus vectors. Gene Ther. 19, 649-58.
53. Ogston, P., Raj, K., and Beard, P. (2000). Productive replication of adeno-associated virus can occur in human papillomavirus type 16 (HPV-16) episome-containing keratinocytes and is augmented by the HPV-16 E2 protein. J. Virol. 74, 3494-504.
54. O'Riordan, C.R., Lachapelle, A., Delgado, C., et al. (1999). PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther. 10, 1349-58.
55. Perabo, L., Endell, J., King, S., et al. (2006). Combinatorial engineering of a gene therapy vector: directed evolution of adenoassociated virus. J. Gene Med. 8, 155-62.
56. Raper, S.E., Wilson, J.M., and Nunes, F.A. (2013). Flushing out antibodies to make aav gene therapy available to more patients. Mol Ther. 21, 269-271.
57. Rapti, K., Hajjar, R.J., and Weber, T. (2012). Novel approaches to deliver molecular therapeutics in cardiac disease using adeno-associated virus vectors. Translational Cardiology, 391-458.
58. Samulski, R.J., Berns, K.I., Tan, M., and Muzyczka, N. (1982). Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl. Acad. Sci. U.S.A. 79, 2077-81.
59. Samulski, R.J., Zhu, X., Xiao, X., et al. (1991). Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J. 10, 3941-50.
60. Senapathy, P., Tratschin, J.D., and Carter, B.J. (1984). Replication of adeno-associated virus DNA. Complementation of naturally occurring rep-mutants by a wild-type genome or an orimutant and correction of terminal palindrome deletions. J. Mol. Biol. 179, 1-20.
61. Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220-5.
62. Sonntag, F., Kother, K., Schmidt, K., et al. (2011). The assemblyactivating protein promotes capsid assembly of different adeno-associated virus serotypes. J. Virol. 85, 12686-97.
63. Stemmer, W.P. (1994). Rapid evolution of a protein in vitro by DNA shuffling. Nature 370, 389-91.
64. Tindall, K.R., and Kunkel, T.A. (1988). Fidelity of DNA synthesis by the Thermus aquaticus DNA polymerase. Biochemistry 27, 6008-13.
65. Tratschin, J.D., West, M.H., Sandbank, T., and Carter, B.J. (1984). A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase. Mol. Cell Biol. 4, 2072-81.
66. Veron, P., Leborgne, C., Monteilhet, V., et al. (2012). Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors. J Immunol. 188, 6418-24.
67. Wang, L., Calcedo, R., Bell, P., et al. (2011). Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. Hum. Gene Ther. 22, 1389-401.